NDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Aug 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
5/8 — Partial
COMBIPATCH (estradiol/norethindrone acetate transdermal system) by Noven Pharmaceuticals is estrogen receptor agonists [moa]. Approved for a woman with a uterus for: treatment of moderate to severe vasomotor symptoms due to menopause. First approved in 1998.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMBIPATCH is a transdermal estradiol/norethindrone acetate combination patch approved in 1998 for treating moderate to severe vasomotor symptoms (hot flashes, night sweats) in menopausal women with an intact uterus. It works as an estrogen receptor agonist, delivering continuous hormone replacement therapy through the skin. The fixed-dose combination provides both estrogen and progestin to reduce vasomotor symptoms while protecting the endometrium.
$5MPart D
LOE ApproachingThis product is approaching loss of exclusivity with minimal Part D spending ($5M) and declining patient volume, indicating a contracted team focused on managed decline rather than growth initiatives.
Mechanism of Action
Estrogen Receptor Agonists
Pharmacologic Class:
Estrogen
Career Relevance
COMBIPATCH is not currently driving active hiring or career growth opportunities, reflecting its approaching LOE and minimal market spending. Professionals on this product are typically managing decline, optimizing operations, and preparing for generic competition rather than building commercial infrastructure.
Worked on COMBIPATCH at Noven Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.